Home › Pulmonary Hypertension › Texas › Dallas
Pulmonary Hypertension clinical trials in Dallas, TX
4 studies for Pulmonary Hypertension are looking for participants at sites in and around Dallas (within about 30 miles). Open a study to see who can join and how to contact the study team.
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
Recruiting
- Baylor University Medical Center, Dallas
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
RecruitingObservational study
- Baylor University Medical Center, Dallas
- UT Southwest Medical Center Heart and Lung Clinic, Dallas
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
Recruiting
- Baylor University Hospital, Dallas
Pulmonary Hypertension Association Registry
RecruitingObservational study
- UT Southwestern Medical Center, Dallas
About Pulmonary Hypertension
Pulmonary hypertension (PH) is high blood pressure in the arteries to your lungs. It makes your heart work harder, which can lead to heart failure.
More about Pulmonary Hypertension on MedlinePlus
Pulmonary Hypertension trials in other cities
- Philadelphia, PA10 studies
- Aurora, CO9 studies
- Phoenix, AZ9 studies
- Kansas City, KS8 studies
- Cincinnati, OH8 studies
- Indianapolis, IN8 studies
- Houston, TX7 studies
- Bend, OR7 studies
- Salt Lake City, UT7 studies
- New York City, NY7 studies
- Charleston, SC7 studies
- Rochester, MN7 studies
Other studies in Dallas
- Breast Cancer54 studies
- Non-Small Cell Lung Cancer52 studies
- Heart Failure42 studies
- Metastatic Cancer42 studies
- Cancer (all types)38 studies
- Prostate Cancer36 studies
- Colorectal Cancer33 studies
- Obesity31 studies
- Ovarian Cancer28 studies
- Bladder Cancer27 studies
- Lung Cancer27 studies
- Endometrial Cancer25 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.